British pharmaceutical company GSK PLC (GSK) and its Massachusetts-based partner Spero Therapeutics (SPRO) said on Wednesday ...

Urinary tract infections are common and unpleasant, but a research team at Vanderbilt University has developed a ...

complicated UTI is a broad term that could include those who are pregnant, immunocompromised, or have a medical condition that could lead to patients requiring more extensive treatment for the ...

In addition, the company is working on another antibiotic to treat complicated UTIs, in which the infection ... hospitalization and a longer course of treatment. That drug could potentially ...

Learn about urinary tract infections (UTIs) - causes, symptoms, treatment, prevention, and risk factors in a comprehensive guide.

A new guideline on complicated urinary tract infections (UTIs) could redefine treatment in Australia and globally. The advice, led by Murdoch Children's Research Institute (MCRI) researchers on ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...

“Complicated UTIs are treated for a longer period of ... In addition to hydration, treatment may include antidiarrheal drugs such as loperamide (Imodium). This medication is not advised for ...

UTIs found in these individuals are considered complicated and would be treated ... in the United States recommend immediate antibiotic treatment for people with symptomatic UTIs.

Shares of Spero Therapeutics gained after the company and GSK ended their trial for a treatment for complicated urinary tract infections early after it met its primary endpoint. The stock more than ...

Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US ...

Spero Therapeutics (SPRO) stock jumps as GSK (GSK) partnered oral UTI treatment, tebipenem HBr, succeeds in a pivotal Phase 3 ...